Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RHAPSODY: INCMGA00012 as Consolidation Therapy in ESCC
NCT04494009Phase 2Active, not recruiting
- Sponsor
- Asan Medical Center
- Start
- Sep 2020
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of retifanlimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Asan Medical Center. Started Sep 2020; status: active, not recruiting.
02
Drugs
retifanlimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04494009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04494009.